Page 24 - Crispr News Today

In a small study, researchers modified patients’ immune cells to target their particular cancer—but it only worked for a third of volunteers.

A phase 1 study showed robust responses in patients with TTR amyloidosis with cardiomyopathy, similar to those reported last year in amyloid polyneuropathy.

A CRIPR gene therapy volunteer recently died. His death is now raising questions. Is gene-editing really safe?

The US government is funding tech to determine whether genetic alterations in a virus or pest are an evolutionary quirk—or a lab-engineered danger.

A Qualitative Research Study accomplished by Data Bridge Market researchs database, titled “Plant Breeding and CRISPR Plant Market” with 100+ market data

In a new study posted to the medRxiv* preprint server, researchers in China developed an MPXV assay combining clustered regularly interspaced short palindromic repeats and CRISPR-associated protein (CRISPR/Cas) and recombinase-aided amplification (RAA) for the first time.

A team led by investigators at Massachusetts General Hospital (MGH) has overcome a major constraint for cutting and editing DNA by CRISPR-Cas enzymes and other technologies.

A team of researchers at Northwestern University has devised a new platform for gene editing that could inform the future application of a near-limitless library of CRISPR-based therapeutics.

Carolyn R. Bertozzi, Morten Meldal and K. Barry Sharpless have been awarded the Nobel Prize in chemistry for developing a way of "snapping molecules together.''

An experiment tests whether the gene-editing technology can stop the virus from replicating, which would ultimately wipe out the infection.